在SARS-CoV-2感染中,Caveolin-1调解神经炎症和认知障碍
bioRxiv : the preprint server for biology
|October 31, 2023
概括
将Caveolin-1 (Cav-1) 向血脑屏障 (BBB) 可能会对抗COVID-19相关的神经炎症. 研究表明,Cav-1缺乏可以保护小鼠免受SARS-CoV-2诱导的T细胞透和认知缺陷.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 病毒学 病毒学
背景情况:
- 白细胞透到中枢神经系统 (CNS) 导致神经炎症和认知障碍.
- 大脑内皮细胞和血脑屏障 (BBB) 是炎症疾病期间免疫细胞贩运的关键调节者.
- 凯沃林-1 (Cav-1) 影响BBB的透性,但其在病毒感染期间T细胞中枢神经系统透中的作用尚不清楚.
研究的目的:
- 用小鼠模型研究BBB的Cav-1在SARS-CoV-2-诱导的神经炎症和认知功能障碍中的作用.
- 为了确定Cav-1的遗传缺陷是否会影响T细胞透和SARS-CoV-2感染后的学习/记忆缺陷.
主要方法:
- 利用SARS-CoV-2小鼠模型检查Cav-1在大脑内皮细胞中的表达.
- 采用Cav-1淘汰赛 (KO) 鼠标来评估Cav-1缺乏对T细胞透 (CD3+) 和认知功能的影响.
- 测量了血管细胞粘附分子-1 (VCAM-1) 在大脑内皮细胞和海马体T细胞透中的表达.
主要成果:
- SARS-CoV-2 感染在大脑内皮细胞中升高了Cav-1 表达的调节.
- 感染导致VCAM-1表达增加和海马体中CD3+T细胞透,与学习和记忆缺陷相关.
- 卡维-1KO小鼠表现出减弱的VCAM-1表达和减少的T细胞透,并受到SARS-CoV-2诱导的认知障碍的保护.
结论:
- 在BBB的Cav-1在SARS-CoV-2介导的神经炎症和认知衰退中发挥着重要作用.
- 准Cav-1可能是缓解COVID-19相关的神经炎症和认知缺陷的治疗策略.
相关概念视频
Alzheimer's Disease: Overview
500
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
500
Cystic Fibrosis: Pathogenesis
256
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
256
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
318
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
318
Role of Cerebellum and Prefrontal Cortex in Memory
449
The cerebellum, while traditionally associated with motor control, also plays a crucial role in memory, particularly in procedural memory, which involves learning motor tasks that become automatic through repetition. For example, studies have shown that when the cerebellum is damaged, individuals or animals lose the ability to learn conditioned motor responses, such as the conditioned eye-blink response in classical conditioning experiments with rabbits. This study demonstrates the...
449
Role of Neurotransmitters in Memory
589
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
589
Alzheimer's Disease: Treatment
200
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
200


